26 April 2018 – Evox Therapeutics Ltd., a leading exosome therapeutics company, announces that it has expanded into a new laboratory and office space at The Oxford Science Park, to enhance its research and development (R&D) capabilities and to facilitate growth of the Company.

Following its inception in 2016, Evox has continued to advance its groundbreaking exosome research. This expansion reflects the growing interest and demand in the exosome-based biotherapeutics field and will provide access to the R&D facilities and equipment needed to accelerate the Company’s growth. 

As part of the move, Evox is expecting to create over a dozen new job opportunities in the area over the near-term.

The new 5,800 square foot space significantly increases the Company’s overall footprint and includes state-of-the-art laboratories, providing cleanroom capabilities and a tissue culture / process development laboratory suitable to prepare material for pre-clinical studies.

Dr Antonin de Fougerolles, Chief Executive Officer of Evox, commented: “We are pleased to be moving into our new, state-of-the-art facilities at The Oxford Science Park. This expansion will accommodate our increase in R&D and expanding pre-clinical pipeline of exosome biotherapeutics.

Our research stems from the innovative work carried out at the University of Oxford; therefore, we look forward to the opportunities provided by this expansion to continue to attract talented new employees in the Oxford region.”

Piers Scrimshaw-Wright, Managing Director of The Oxford Science Park, added: “We are delighted to see Evox Therapeutics expanding on The Oxford Science Park as its R&D progresses. It is one of several University of Oxford spin-outs on the Park, cementing our reputation as the place to locate for life sciences business in Oxford.”